Immunology · 2022 · 11 citations · 39 references
Life SciencesImmunologyMolecular BiologyCell SignalingMolecular VirologyVirologyAdaptor Protein ComplexesAntiviral ImmunityAntiviral TherapyInnate Immune Signaling PathwaysInterferon ResponsesProtein DegradationAntiviral Interferon ResponsesAntiviral TreatmentE3 Ubiquitin Ligase Substrate RecognitionInterferon Response To Viral InfectionProtein StabilityRegulation By E3 Ubiquitin LigasesType I Interferon PathwaysType I Interferon Responses
Type I interferon (IFN-I) is a common biological molecule used for the treatment of viral diseases. However, the clinical antiviral efficacy of IFN-I needs to be greatly improved. In this study, IFN-I receptor 2 (IFNAR2) was revealed to undergo degradation at the protein level in cells treated with IFN-I for long periods of time. Further studies found a physical interaction between the E3 ubiquitin ligase midline-1 (MID1) and IFNAR2. As a consequence, MID1 induced both K48- and K63-linked polyubiquitination of IFNAR2, which promoted IFNAR2 protein degradation in a lysosome-dependent manner. Conversely, knockdown of MID1 largely restricted IFN-I-induced degradation of IFNAR2. Importantly, MID1 regulated the strength of IFN-I signalling and IFN-I-induced antiviral activity. These findings reveal a regulatory mechanism of IFNAR2 ubiquitination and protein stability in IFN-I signalling, which could provide a potential target for improving the antiviral efficacy of IFN-I.
39